NO921050L - Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister - Google Patents

Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Info

Publication number
NO921050L
NO921050L NO92921050A NO921050A NO921050L NO 921050 L NO921050 L NO 921050L NO 92921050 A NO92921050 A NO 92921050A NO 921050 A NO921050 A NO 921050A NO 921050 L NO921050 L NO 921050L
Authority
NO
Norway
Prior art keywords
histamine
subject
agent
receptor agonists
receptor
Prior art date
Application number
NO92921050A
Other languages
English (en)
Other versions
NO921050D0 (no
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Estero Anstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estero Anstalt filed Critical Estero Anstalt
Publication of NO921050L publication Critical patent/NO921050L/no
Publication of NO921050D0 publication Critical patent/NO921050D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO921050A 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister NO921050D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19
PCT/SE1990/000599 WO1991004037A1 (en) 1989-09-19 1990-09-19 Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists

Publications (2)

Publication Number Publication Date
NO921050L true NO921050L (no) 1992-03-18
NO921050D0 NO921050D0 (no) 1992-03-18

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO921050A NO921050D0 (no) 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Country Status (12)

Country Link
US (1) US5348739A (no)
EP (1) EP0493468B1 (no)
JP (1) JP2845622B2 (no)
KR (1) KR100195392B1 (no)
AT (1) ATE136786T1 (no)
AU (1) AU640954B2 (no)
CA (1) CA2066728C (no)
DE (1) DE69026620T2 (no)
DK (1) DK0493468T3 (no)
ES (1) ES2087163T3 (no)
NO (1) NO921050D0 (no)
WO (1) WO1991004037A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
WO1999019462A1 (en) 1997-10-10 1999-04-22 The Regents Of The University Of California Enhanced immunogenic cell populations prepared using h2 receptor antagonists
CA2341742A1 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
IL146745A0 (en) * 1999-07-16 2002-07-25 Maxim Pharm Inc Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
JP2006512279A (ja) * 2002-03-29 2006-04-13 マキシム ファーマシューティカルス，インコーポレイテッド 眼内損傷を治療および予防するためのｒｏｍ生成および放出阻害剤の使用
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
AU2008221358A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US20120039844A1 (en) * 2009-04-16 2012-02-16 Kristoffer Hellstrand Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
CA3068587A1 (en) * 2017-06-29 2019-01-03 Immune Pharmaceuticals, Inc. Methods of delaying and preventing acute myeloid leukemia relapse
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
JP2845622B2 (ja) 1999-01-13
AU6419190A (en) 1991-04-18
CA2066728C (en) 2001-12-25
EP0493468B1 (en) 1996-04-17
CA2066728A1 (en) 1991-03-20
WO1991004037A1 (en) 1991-04-04
ATE136786T1 (de) 1996-05-15
AU640954B2 (en) 1993-09-09
EP0493468A1 (en) 1992-07-08
NO921050D0 (no) 1992-03-18
KR920703078A (ko) 1992-12-17
JPH05504548A (ja) 1993-07-15
DE69026620D1 (de) 1996-05-23
KR100195392B1 (ko) 1999-06-15
DE69026620T2 (de) 1996-10-02
DK0493468T3 (da) 1996-08-26
US5348739A (en) 1994-09-20
ES2087163T3 (es) 1996-07-16

Similar Documents

Publication Publication Date Title
NO921050D0 (no) Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister
Goldstein et al. The role of interferon in cancer therapy: a current perspective
DK0565587T3 (da) Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.
Miller Intratumor immunologic heterogeneity
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
ES8502405A1 (es) Un metodo para producir una emulsion acuosa de perfluorocarburo
IT8548348A0 (it) Derivati di amminofenolo,procedimento per prepararli e composizione farmaceutica che li contiene
Baguley et al. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
Chiodoni et al. Different requirements for α‐galactosylceramide and recombinant IL‐12 antitumor activity in the treatment of C‐26 colon carcinoma hepatic metastases
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
NL7701304A (nl) Stimuleermiddelen voor (beta)-adrenoreceptors en werkwijze ter bereiding daarvan.
PH13417A (en) Thiourea and guanidine derivative having actively as hestamine h2 receptor antagonists and pharmaceuas histamine h2 receptor artagonists and pharmaceutical composition
Alpaugh et al. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
Maeda et al. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma
DK72591A (da) Hidtil ukendt s-timolol-derivat samt fremgangsmaade til fremstilling deraf
Chao et al. Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma
KR850006429A (ko) 새로운 시아노이미다졸 누클레오시드 유도체 및 그 제조방법
Pereira et al. The effect of nicotinamide adenine dinucleotide on lipolysis in adipose tissue in vitro
JPH07196490A (ja) 癌転移抑制剤
Rochlitz et al. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors
Gold et al. Autolymphocyte therapy—I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response